A First-in-human Trial of GRT7041 in Healthy Participants
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Treatment of Pain
In brief
The purpose of this trial is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GRT7041 in healthy male and female (Women of non-childbearing potential) participants. The trial duration will be up to approximately 6 weeks for participants in Part 1 (Single ascending dose \[SAD\]), except for participants taking part in the food effect cohort SAD3 where the trial duration will be up to approximately 8 weeks. The trial duration will be up to approximately 7 weeks in Part 2 (Multiple ascending dose \[MAD\]), and the Treatment Period will be up to 14 days (for Part 2). The trial will include a Screening Visit, an in-house stay period and Follow-up (FU) Visit/End-of-Trial (EoT) Visit.
Key facts
- Study ID
- NCT07289776
- Run by
- Grünenthal GmbH
- People needed
- 70
- Starts
- 2026-01-14
- Expected to finish
- 2026-08-28
- Last updated by the study team
- 2026-02-20
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.
Where it is running
- New Zealand Clinical Research (NZCR) — Christchurch, New Zealand (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.